GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3266)

  • GC74187 structure
    GC74187Salicylic acid-13C6
    CAS: 1189678-81-6
    Purity: >97.00%

    Salicylic acid-13C6 es el ácido salicílico marcado con 13c.

  • GC74252 structure
    GC74252Euphornin
    CAS: 80454-47-3
    Purity: >98.00%

    Euphornin es un agente anticaner, que puede ser aislado de E. helioscopia.

  • GC74256 structure
    GC74256Condurango glycoside A
    CAS: 11051-90-4
    Purity: >95.00%

    Condurango glycoside A es un activador de p53.

  • GC74267 structure
    GC74267Propylparaben-d4
    CAS: 1219802-67-1
    Purity: >99.00%

    Propylparaben-d4 es el deuterio etiquetado Propylparaben.

  • GC74270 structure
    GC74270Penduletin
    CAS: 569-80-2
    Purity: >99.00%

    Penduletin es una flavona, que puede ser aislada de Brickelia pendula y Vitex negundo.

  • GC74305 structure
    GC74305CD24/Siglec-10 blocking peptide, CSBP
    Purity: >99.00%

    CD24/Siglec-10 blocking peptide, CSBP no sólo puede bloquear la interacción de CD24/Siglec-10, sino también PD-1/PD-L1.

  • GC74313 structure
    GC74313MYBMIM
    Purity: >99.00%

    MYBMIM es un inhibidor para el ensambdel complejo molecular MYB:CBP/P300.

  • GC74358 structure
    GC74358PNC-27 acetate
    Purity: >99.00%

    PNC-27 acetate, un péptido quimérico p53-penetratina se une a HDM-2 en una estructura similar a un pép53, induce la formación selectiva de poros membranosos y conduce a la lisis de células cancerosas.

  • GC74380 structure
    GC74380Ac-VRPR-AMC TFA
    Purity: >99.00%

    Ac-VRPR-AMC TFA es un sustrde metacaspasa fluorogénica.

  • GC74422 structure
    GC74422Duvakitug
    CAS: 2750005-84-4
    Purity: >99.00%

    Duvakitug es un anticuerpo monoclonal IgG1- − 2 dirigido a TNFSF15/TL1A.

  • GC74424 structure
    GC74424Boserolimab
    CAS: 2444297-08-7
    Purity: >99.00%

    Boserolimab (MK-5890) es un anticuerpo monoclonal agonista humanique se une a CD27 para proporcionar una señal coestimulante que mejora las respuestas mediadas por células t.

  • GC74430 structure
    GC74430Exlinkibart
    CAS: 2642171-64-8
    Purity: >99.00%

    Exlinkibart (LVGN-6051) se dirige a TNFRSF9 y es un anticuerpo IgG1κ humania través de la tecnología de injerto de región de determinación de complementariedad (CDR).

  • GC74441 structure
    GC74441Evunzekibart
    CAS: 2639688-77-8
    Purity: >97.00%

    Evunzekibart (ATOR-1017) es un agonista condicional del receptor Fc-γ 4-1BB y un anticuerpo tipo IgG4.

  • GC74449 structure
    GC74449Vonsetamig
    CAS: 2408319-33-3
    Purity: >95.00%

    Vonsetamig es una inmunoglobulina humanig4-kappa, anti-TNFRSF17 y un anticuerpo monoclonal CD3E.

  • GC74460 structure
    GC74460Visugromab
    CAS: 2556646-63-8
    Purity: >98.00%

    Visugromab (CTL-002) es un neutrgdf-15 IgG4 mAb.

  • GC74462 structure
    GC74462Zimberelimab
    CAS: 2259860-24-5
    Purity: >99.00%

    Zimberelimab (GLS-010) es un anticuerpo monoclonal IgG4 anti-PD-1 totalmente humano con una EC50 de 210 pM para PD-1 humano.

  • GC74464 structure
    GC74464Cadonilimab
    CAS: 2394841-59-7
    Purity: >99.00%

    Cadonilimab (AK104) es un anticuerpo tetravalente IgG1 biespecífico dirigido a PD1/CTLA4.

  • GC74467 structure
    GC74467Cemiplimab
    CAS: 1801342-60-8
    Purity: >99.00%

    Cemiplimab (anti-pd-1 humano) es un anticuerpo monoclonal IgG4 receptor de muerte programada de alta afinidad (PD-1) que bloquea la supresión de células t mediada por PD-1/PD-L1.

  • GC74469 structure
    GC74469Tabalumab
    CAS: 1143503-67-6
    Purity: >98.00%

    Tabalumab (LY2127399) es un anticuerpo monoclonal humano anti-baf(factor activador de células b) (tipo IgG4) con actividad neutralizcontra bafunido a la membrana y soluble.

  • GC74472 structure
    GC74472Conatumumab
    CAS: 896731-82-1
    Purity: >98.00%

    Conatumumab (AMG 655) es un anticuerpo agonista monoclonal humano contra el receptor de muerte humana 5 (DR5, TRAILR2) (Kd: 1 nM para la forma larga de DR5, 0,8 nM para la forma corta de DR5).

  • GC74476 structure
    GC74476Seribantumab
    CAS: 1334296-12-6
    Purity: >95.00%

    Seribantumab (MM 121) es un anticuerpo monoclonal IgG2 totalmente humano que se dirige a HER3.

  • GC74477 structure
    GC74477Tigatuzumab
    CAS: 918127-53-4
    Purity: >95.00%

    Tigatuzumab (CS-1008) es un anticuerpo monoclonal humaniigg1 diana receptor de muerte 5 (DR5).

  • GC74482 structure
    GC74482Drozitumab
    CAS: 912628-39-8
    Purity: >99.00%

    Drozitumab (PRO 95780) es un anticuerpo monoclonal agonista humano que se une al receptor de muerte DR5.

  • GC74486 structure
    GC74486Lexatumumab
    CAS: 845816-02-6
    Purity: >96.00%

    Lexatumumab (HGS-ETR 2) es un anticuerpo monoclonal de tipo IgG4κ.